vs
Side-by-side financial comparison of FRESH DEL MONTE PRODUCE INC (FDP) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
FRESH DEL MONTE PRODUCE INC is the larger business by last-quarter revenue ($1.0B vs $346.4M, roughly 3.0× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 1.0%, a 27.1% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs -4.9%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs -4.3%).
Fresh Del Monte Produce Incorporated is one of the world’s leading vertically integrated producers, distributors, and marketers of prepared, fresh and fresh-cut fruits and vegetables. Incorporated in George Town, Cayman Islands, its US executive office is located at 241 Sevilla Avenue, Coral Gables, Florida.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
FDP vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $346.4M |
| Net Profit | $10.7M | $97.3M |
| Gross Margin | 8.5% | 57.2% |
| Operating Margin | 1.9% | 36.1% |
| Net Margin | 1.0% | 28.1% |
| Revenue YoY | -4.9% | 4.8% |
| Net Profit YoY | -67.8% | — |
| EPS (diluted) | $0.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.0B | $346.4M | ||
| Q4 25 | $1.0B | $339.0M | ||
| Q3 25 | $1.0B | $327.3M | ||
| Q2 25 | $1.2B | $321.4M | ||
| Q1 25 | $1.1B | $330.6M | ||
| Q4 24 | $1.0B | $348.5M | ||
| Q3 24 | $1.0B | $345.5M | ||
| Q2 24 | $1.1B | $336.2M |
| Q1 26 | $10.7M | $97.3M | ||
| Q4 25 | $32.3M | $44.7M | ||
| Q3 25 | $-29.1M | $38.7M | ||
| Q2 25 | $56.8M | $34.0M | ||
| Q1 25 | $31.1M | $58.0M | ||
| Q4 24 | $20.3M | $37.5M | ||
| Q3 24 | $42.1M | $33.8M | ||
| Q2 24 | $53.6M | $38.4M |
| Q1 26 | 8.5% | 57.2% | ||
| Q4 25 | 10.4% | 59.7% | ||
| Q3 25 | 7.9% | 59.5% | ||
| Q2 25 | 10.2% | 59.8% | ||
| Q1 25 | 8.4% | 58.4% | ||
| Q4 24 | 6.8% | 55.5% | ||
| Q3 24 | 9.2% | 54.2% | ||
| Q2 24 | 9.9% | 52.0% |
| Q1 26 | 1.9% | 36.1% | ||
| Q4 25 | 4.5% | 19.9% | ||
| Q3 25 | -2.1% | 17.9% | ||
| Q2 25 | 5.8% | 16.8% | ||
| Q1 25 | 4.1% | 21.6% | ||
| Q4 24 | 3.0% | 16.9% | ||
| Q3 24 | 5.3% | 15.0% | ||
| Q2 24 | 6.0% | 11.8% |
| Q1 26 | 1.0% | 28.1% | ||
| Q4 25 | 3.2% | 13.2% | ||
| Q3 25 | -2.8% | 11.8% | ||
| Q2 25 | 4.8% | 10.6% | ||
| Q1 25 | 2.8% | 17.5% | ||
| Q4 24 | 2.0% | 10.8% | ||
| Q3 24 | 4.1% | 9.8% | ||
| Q2 24 | 4.7% | 11.4% |
| Q1 26 | $0.21 | — | ||
| Q4 25 | $0.67 | $0.95 | ||
| Q3 25 | $-0.61 | $0.81 | ||
| Q2 25 | $1.18 | $0.70 | ||
| Q1 25 | $0.64 | $1.17 | ||
| Q4 24 | $0.41 | $0.74 | ||
| Q3 24 | $0.88 | $0.66 | ||
| Q2 24 | $1.12 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.3M | $245.4M |
| Total DebtLower is stronger | $451.5M | $1.2B |
| Stockholders' EquityBook value | $2.0B | $796.3M |
| Total Assets | $3.4B | $2.4B |
| Debt / EquityLower = less leverage | 0.22× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $66.3M | $245.4M | ||
| Q4 25 | $35.7M | $363.4M | ||
| Q3 25 | $97.2M | $296.4M | ||
| Q2 25 | $85.5M | $292.9M | ||
| Q1 25 | $34.4M | $306.8M | ||
| Q4 24 | $32.6M | $320.8M | ||
| Q3 24 | $50.8M | $299.3M | ||
| Q2 24 | $37.8M | $344.4M |
| Q1 26 | $451.5M | $1.2B | ||
| Q4 25 | $176.2M | $1.2B | ||
| Q3 25 | $176.7M | $1.2B | ||
| Q2 25 | $205.2M | $1.2B | ||
| Q1 25 | $237.4M | $1.2B | ||
| Q4 24 | $248.9M | — | ||
| Q3 24 | $274.8M | — | ||
| Q2 24 | $290.4M | — |
| Q1 26 | $2.0B | $796.3M | ||
| Q4 25 | $2.0B | $911.5M | ||
| Q3 25 | $2.0B | $849.2M | ||
| Q2 25 | $2.1B | $882.3M | ||
| Q1 25 | $2.0B | $820.8M | ||
| Q4 24 | $2.0B | $906.9M | ||
| Q3 24 | $2.0B | $878.9M | ||
| Q2 24 | $2.0B | $905.4M |
| Q1 26 | $3.4B | $2.4B | ||
| Q4 25 | $3.1B | $2.5B | ||
| Q3 25 | $3.1B | $2.4B | ||
| Q2 25 | $3.2B | $2.5B | ||
| Q1 25 | $3.2B | $2.5B | ||
| Q4 24 | $3.1B | $2.5B | ||
| Q3 24 | $3.2B | $2.5B | ||
| Q2 24 | $3.1B | $2.5B |
| Q1 26 | 0.22× | 1.53× | ||
| Q4 25 | 0.09× | 1.34× | ||
| Q3 25 | 0.09× | 1.44× | ||
| Q2 25 | 0.10× | 1.39× | ||
| Q1 25 | 0.12× | 1.49× | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $44.1M | $293.2M |
| Free Cash FlowOCF − Capex | — | $209.9M |
| FCF MarginFCF / Revenue | — | 60.6% |
| Capex IntensityCapex / Revenue | 1.4% | 9.5% |
| Cash ConversionOCF / Net Profit | 4.12× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $44.1M | $293.2M | ||
| Q4 25 | $10.9M | $93.6M | ||
| Q3 25 | $75.0M | $111.3M | ||
| Q2 25 | $113.1M | $17.4M | ||
| Q1 25 | $46.1M | $116.6M | ||
| Q4 24 | $-4.7M | $43.8M | ||
| Q3 24 | $43.5M | $48.8M | ||
| Q2 24 | $125.0M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $-17.2M | $87.2M | ||
| Q3 25 | $60.9M | $106.3M | ||
| Q2 25 | $101.5M | $13.6M | ||
| Q1 25 | $36.1M | $100.9M | ||
| Q4 24 | $-22.3M | $35.2M | ||
| Q3 24 | $30.1M | $39.4M | ||
| Q2 24 | $117.0M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | -1.7% | 25.7% | ||
| Q3 25 | 6.0% | 32.5% | ||
| Q2 25 | 8.6% | 4.2% | ||
| Q1 25 | 3.3% | 30.5% | ||
| Q4 24 | -2.2% | 10.1% | ||
| Q3 24 | 3.0% | 11.4% | ||
| Q2 24 | 10.3% | -9.8% |
| Q1 26 | 1.4% | 9.5% | ||
| Q4 25 | 2.8% | 1.9% | ||
| Q3 25 | 1.4% | 1.5% | ||
| Q2 25 | 1.0% | 1.2% | ||
| Q1 25 | 0.9% | 4.7% | ||
| Q4 24 | 1.7% | 2.5% | ||
| Q3 24 | 1.3% | 2.7% | ||
| Q2 24 | 0.7% | 1.7% |
| Q1 26 | 4.12× | 3.01× | ||
| Q4 25 | 0.34× | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | 1.99× | 0.51× | ||
| Q1 25 | 1.48× | 2.01× | ||
| Q4 24 | -0.23× | 1.17× | ||
| Q3 24 | 1.03× | 1.44× | ||
| Q2 24 | 2.33× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDP
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
